The 2008 World Health Organization classification system for myeloproliferative neoplasms

Abstract

The first formal classification of chronic myeloid neoplasms is credited to William Dameshek, who in 1951 described the concept of “myeloproliferative disorders (MPD)” by grouping together chronic myelogenous leukemia, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2001 World Health Organization (WHO) classification of myeloid malignancies included these MPDs under the broader category of chronic myeloproliferative diseases (CMPD), which also included chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES), and “CMPD, unclassifiable.” The revised 2008 WHO classification system featured the following changes: 1) the term “CMPD” was replaced by “myeloproliferative neoplasm (MPN),” 2) mast cell disease was formally included under the category of MPN, and 3) the subcategory of CEL/HES was reorganized into “CEL not otherwise specified (CEL‐NOS)” and “myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1”; CEL‐NOS remained a subcategory of “MPN,” whereas the latter neoplasms were now assigned a new category of their own. Furthermore, diagnostic criteria for PV, ET, and PMF were revised by incorporating recently described molecular markers (eg, JAK2 and MPL mutations) as well as underscoring the role of histology in differentiating reactive from clonal myeloproliferations. As a result, red cell mass measurement is no longer necessary for the diagnosis of PV, and ET can now be diagnosed at a lower platelet count threshold. The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of myeloid malignancies. Cancer 2009. © 2009 American Cancer Society.

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

“…2,5,13 Diagnosis of MCL was based on the presence of at least 20% mast cells in BM smears with or without C-findings. The diagnosis AHNMD was established by evaluating peripheral blood (PB, e.g.…”

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

“…To address this issue, 1,297 ET patients followed by the Lazio Cooperative Group and the Bologna University Hospital between 1979 and 2013 were retrospectively analyzed to correlate spleen enlargement with baseline disease characteristics and outcome, with particular focus on thrombotic risk. [17] after the application of these new definitions. Spleen enlargement was defined as a palpable spleen under costal margin [18].…”

Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia

“…The French-American-British (FAB) classification system divides AML into 8 subtypes, M0 to M7, based on the type of cell from which the leukemia developed and the cell's degree of maturity [1].…”